Skip to main content

News Releases & Statements

News Releases & Statements

New Drug Approval Expands Options For Patients with Rare Marginal Zone Lymphoma and Advanced Follicular Lymphoma

Rye Brook, N.Y. (February 5, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splenic MZL. It is considered a slow growing disease with generally favorable outcome. Read More


FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder

Rye Brook, N.Y. January 19, 2021 – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (Cytoxan® or Neosar®), plus the corticosteroid dexamethasone in these patients.

Read More

The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills

Rye Brook, NY (December 21, 2020) - The Leukemia & Lymphoma Society issues the following statement in response to Congress including policies designed to protect patients from surprise medical bills in the stimulus bill scheduled for a vote Monday, Dec. 21, 2020:

LLS applauds Congress for reaching a bipartisan agreement that will, after years of work, hold patients harmless from surprise medical bills. 

Read More


Rye Brook, N.Y. (December 18, 2020) – The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade®) and the corticosteroid dexamethasone in these patients.

Read More

The Leukemia & Lymphoma Society Statement on COVID-19 Vaccine Distribution

At The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives. As a patient-focused leader in the scientific and medical community, we are encouraged by the U.S. Food & Drug Administration (FDA) decision to grant emergency use authorization (EUA) to the first COVID-19 vaccine in the U.S.

Read More

Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants

Rye Brook, NY (December 14, 2020) – As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the economy, education, business and science, including the blood cancer community. Blood cancers don’t stop for the Covid-19 virus and the urgent need for collaboration to address these challenges has never been starker.

Read More

LLS Statement on Oral Arguments in California v. Texas

Rye Brook, NY (November 9, 2020) – This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act.

The following is a statement from The Leukemia & Lymphoma Society’s Chief Medical Officer Gwen Nichols, M.D.:

Read More

The Hairy Cell Leukemia Foundation and The Leukemia & Lymphoma Society Join Forces to Find New Therapies for Patients with this Rare Blood Cancer

New York, NY and Rye Brook, NY (November 2, 2020) - The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) announced today they are teaming up to support a research grants program of up to $10 million over five years, to build a more comprehensive understanding of hairy cell leukemia (HCL), develop better therapies and optimize outcomes for patients with HCL.

Read More

Media Requests

Please send all media-related inquiries and interview requests to  An LLS representative will respond as soon as possible.